Manal F Abdelmalek
Manal F Abdelmalek is an expert in Hepatology at Mayo Clinic (United States, Rochester) (United States). As of October 2026, ScienceLeadR ranks Manal F Abdelmalek in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Liver Cirrhosis. Manal F Abdelmalek has authored 334 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 2 of them ongoing. SLR score: 1,703 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Endocrinology - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 334
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Psoas Muscle Trajectory and Survival After Liver Transplantation for Steatotic Liver Disease in Severe Obesity. PMID 42171888 — liver diseases, liver transplantation, body mass index, muscles, psoas muscles, gastroenterology, liver, obesity, transplants, obesity, morbid, transplantation | Dig Dis Sci | 2026 | 0 |
| Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis. PMID 42142900 — life style, fibrosis, non-alcoholic fatty liver disease, therapeutics | Clin Liver Dis | 2026 | 0 |
| Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α. PMID 42092280 — liver diseases, hepatocytes, receptor, par-2, fibrosis, non-alcoholic fatty liver disease, dyslipidemias, weight gain, receptors, proteinase-activated, repression, psychology, diet, high-fat, liver, diet, cholesterol, peptide hydrolases, body weight, obesity, factor xa, triglycerides | JHEP Rep | 2026 | 0 |
| Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD. PMID 41976355 — liver diseases, simvastatin, non-alcoholic fatty liver disease, neoplasms, liver, electronic health records, liver neoplasms, sex, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors | Cancers (Basel) | 2026 | 0 |
| Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. PMID 41950980 — liver diseases, research design, fibrosis, non-alcoholic fatty liver disease, liver, therapeutics, liver stiffness, semaglutide | Clin Gastroenterol Hepatol | 2026 | 1 |
Clinical Studies 30
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis NCT05720663 — liver diseases, hemorrhage, fibrosis, non-alcoholic fatty liver disease, liver, alcoholics, fatty liver, fatty liver, alcoholic | N/A | Recruiting | 2023 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map